Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MBRX 
Moleculin Biotech Inc (MBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75.83% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.50M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 2893137 | Beta 1.94 | 52 Weeks Range 0.40 - 5.91 | Updated Date 04/2/2025 |
52 Weeks Range 0.40 - 5.91 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.04 |
Earnings Date
Report Date 2025-03-20 | When After Market | Estimate - | Actual -0.557 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.45% | Return on Equity (TTM) -141.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8958421 | Price to Sales(TTM) - |
Enterprise Value 8958421 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.52 | Shares Outstanding 13302500 | Shares Floating 2504751 |
Shares Outstanding 13302500 | Shares Floating 2504751 | ||
Percent Insiders 0.75 | Percent Institutions 3.49 |
Analyst Ratings
Rating 4 | Target Price 18 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Moleculin Biotech Inc
Company Overview
History and Background
Moleculin Biotech, Inc. was founded in 2003. It is a clinical-stage pharmaceutical company focused on developing drug candidates for the treatment of tumors and viruses. It has transitioned through various stages of research and development, primarily focusing on oncology.
Core Business Areas
- Annamycin: Annamycin is Moleculinu2019s next-generation anthracycline designed to avoid multidrug resistance mechanisms. It is being developed for treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcomas.
- WP1066: WP1066 is an inhibitor of STAT3 signaling, a transcription factor implicated in cancer development and immune suppression. It is being developed as a potential treatment for solid tumors.
- WP1220: WP1220 is a pre-clinical stage antiviral drug candidate targeting SARS-CoV-2 and other viruses.
Leadership and Structure
Walter Klempner serves as Chairman and CEO. The company has a typical corporate structure with a board of directors and various departments overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Annamycin: Annamycin is being developed for relapsed or refractory AML. Market share data is not yet available as the drug is still in clinical trials. Competitors include existing AML treatments like chemotherapy and targeted therapies from companies such as AbbVie (Venclexta) and Novartis (Rydapt).
- WP1066: WP1066 is in pre-clinical development for solid tumors. Market share data is unavailable. Competitors include companies developing other STAT3 inhibitors and treatments for solid tumors.
- WP1220: WP1220 is a pre-clinical stage antiviral. Market share data is unavailable. Competitors include companies developing antiviral drugs such as Gilead (Remdesivir) and Pfizer (Paxlovid).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. It involves significant R&D investment and clinical trials. The oncology market is a major segment, and the antiviral market fluctuates with disease outbreaks.
Positioning
Moleculin Biotech is a small, clinical-stage company focused on developing novel therapies. Its competitive advantage lies in its proprietary drug candidates and their potential to address unmet medical needs.
Total Addressable Market (TAM)
The TAM for AML therapies is significant, estimated to be in the billions of dollars. Moleculin Biotech is aiming to capture a portion of this market with Annamycin. The TAM for solid tumors and antiviral therapies is also very large, and the company is positioned to address niche segments within these markets.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates (Annamycin, WP1066, WP1220)
- Potential to address unmet medical needs in oncology and virology
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small size and lack of established commercial infrastructure
- High risk of failure in drug development
Opportunities
- Positive clinical trial results for Annamycin
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Government funding and grants
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- GILD
- PFE
Competitive Landscape
Moleculin Biotech faces intense competition from larger pharmaceutical companies with greater resources. Its success depends on demonstrating superior efficacy and safety of its drug candidates.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on the advancement of its drug candidates through clinical trials. The company has experienced periods of rapid stock appreciation following positive news.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst projections are highly speculative and subject to change. Need the updated data to provide real data
Recent Initiatives: Recent initiatives include advancing Annamycin in clinical trials for AML and soft tissue sarcomas, and preclinical development of WP1220 as an antiviral.
Summary
Moleculin Biotech is a high-risk, high-reward clinical-stage company with promising drug candidates in oncology and virology. Its success hinges on positive clinical trial outcomes, which could drive significant stock appreciation. The company faces challenges related to funding, regulatory hurdles, and competition from larger players. Investors should carefully consider the risks associated with investing in biotechnology companies at this stage of development.
Similar Companies
APLS
Apellis Pharmaceuticals Inc
APLS
Apellis Pharmaceuticals Inc
BLRX
BioLineRx Ltd
BLRX
BioLineRx Ltd
KPTI
Karyopharm Therapeutics Inc
KPTI
Karyopharm Therapeutics Inc
VTVT
vTv Therapeutics Inc
VTVT
vTv Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. Financial data is based on the most recent available information and may not be current.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moleculin Biotech Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2016-06-02 | Co-Founder, Chairman, President & CEO Mr. Walter V. Klemp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://moleculin.com |
Full time employees 17 | Website https://moleculin.com | ||
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.